ArticleFrontiers in pharmacology2026

Case Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftor.

Keirran Hiscock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.